Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients

Journal of Proteomics

Volumn 75, Issue 7, 2012, Pages 2080-2092

  Zellner, Maria ^a   Baureder, Michael ^a   Rappold, Eduard ^b   Bugert, Peter ^c   Kotzailias, Nicole ^a   Babeluk, Rita ^a   Baumgartner, Roland ^a   Attems, Johannes ^d   Gerner, Christopher ^e   Jellinger, Kurt ^f   Roth, Erich ^a   Oehler, Rudolf ^a   Umlauf, Ellen ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Otto Wagner Spital   (Austria)

^c Institute of Transfusion Medicine and Immunology   (Germany)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Ageing; Alzheimer's disease; Dementia; Mao B; Parkinson's disease; Platelets proteomics

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; MESSENGER RNA;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE DURATION; ELECTROPHORESIS; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENETIC ANALYSIS; GENOTYPING TECHNIQUE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NON DEMENTED PARKINSON DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLATELET PROTEOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PLATELETS; DOPAMINE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; PARKINSON DISEASE; PROTEOME; UP-REGULATION;

EID: 84858752466     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.01.014     Document Type: Article

References (73)

1. Da Prada M., Cesura A.M., Launay J.M., Richards J.G. Platelets as a model for neurones?. Experientia Feb 15 1988, 44(2):115-126.
2. Reed G.L., Fitzgerald M.L., Polgar J. Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood Nov 15 2000, 96(10):3334-3342.
3. Vignini A., Nanetti L., Moroni C., Tanase L., Bartolini M., Luzzi S., et al. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol Aging Jul 2007, 28(7):987-994.
4. Colciaghi F., Marcello E., Borroni B., Zimmermann M., Caltagirone C., Cattabeni F., et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology Feb 10 2004, 62(3):498-501.
5. Gattaz W.F., Cairns N.J., Levy R., Forstl H., Braus D.F., Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1996, 246(3):129-131.
6. Kawamoto E.M., Munhoz C.D., Glezer I., Bahia V.S., Caramelli P., Nitrini R., et al. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease. Neurobiol Aging Jun 2005, 26(6):857-864.
7. Grunblatt E., Schlosser R., Fischer P., Fischer M.O., Li J., Koutsilieri E., et al. Oxidative stress related markers in the "VITA" and the centenarian projects. Neurobiol Aging Apr 2005, 26(4):429-438.
8. Parnetti L., Reboldi G.P., Santucci C., Santucci A., Gaiti A., Brunetti M., et al. Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging (Milano) Jun 1994, 6(3):201-207.
9. Jarman J., Glover V., Sandler M., Turjanski N., Stern G. Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation. J Neural Transm Park Dis Dement Sect 1993, 5(1):1-4.
10. Adolfsson R., Gottfries C.G., Oreland L., Wiberg A., Winblad B. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci Sep 22 1980, 27(12):1029-1034.
11. Robinson D.S., Davis J.M., Nies A., Ravaris C.L., Sylwester D. Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets. Arch Gen Psychiatry Jun 1971, 24(6):536-539.
12. Sevush S., Jy W., Horstman L.L., Mao W.W., Kolodny L., Ahn Y.S. Platelet activation in Alzheimer disease. Arch Neurol Apr 1998, 55(4):530-536.
13. Stellos K., Panagiota V., Kogel A., Leyhe T., Gawaz M., Laske C. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J Cereb Blood Flow Metab Nov 2010, 30(11):1817-1820.
14. Bortolato M., Chen K., Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev Oct 2008, 60(13-14):1527-1533.
15. Muck-Seler D., Presecki P., Mimica N., Mustapic M., Pivac N., Babic A., et al. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry Oct 1 2009, 33(7):1226-1231.
16. Wiltfang J., Lewczuk P., Riederer P., Grunblatt E., Hock C., Scheltens P., et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005, 6(2):69-84.
17. Parsian A., Racette B., Zhang Z.H., Rundle M., Perlmutter J.S. Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups. Genomics Mar 2004, 83(3):454-460.
18. Chen M.L., Chen C.H. Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. J Psychiatr Res Jan 2007, 41(1-2):57-62.
19. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259.
20. Hughes A.J., Daniel S.E., Blankson S., Lees A.J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol Feb 1993, 50(2):140-148.
21. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol Oct 1997, 56(10):1095-1097.
22. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch Neurol Nov 1985, 42(11):1097-1105.
23. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology Apr 1991, 41(4):479-486.
24. Kalaria R.N., Kenny R.A., Ballard C.G., Perry R., Ince P., Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci Nov 15 2004, 226(1-2):75-80.
25. Larsen J.P., Dupont E., Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand Apr 1994, 89(4):242-251.
26. Rajput A.H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci Aug 1991, 18(3):275-278.
27. Brucke T., Asenbaum S., Pirker W., Djamshidian S., Wenger S., Wober C., et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997, 50:9-24.
28. Rolf N., Knoefler R., Suttorp M., Kluter H., Bugert P. Optimized procedure for platelet RNA profiling from blood samples with limited platelet numbers. Clin Chem Jun 2005, 51(6):1078-1080.
29. Zellner M., Winkler W., Hayden H., Diestinger M., Eliasen M., Gesslbauer B., et al. Quantitative validation of different protein precipitation methods in proteome analysis of blood platelets. Electrophoresis Jun 2005, 26(12):2481-2489.
30. Winkler W., Zellner M., Diestinger M., Babeluk R., Marchetti M., Goll A., et al. Biological variation of the platelet proteome in the elderly population and its implication for biomarker research. Mol Cell Proteomics Jan 2008, 7(1):193-203.
31. Slany A., Haudek V.J., Gundacker N.C., Griss J., Mohr T., Wimmer H., et al. Introducing a new parameter for quality control of proteome profiles: consideration of commonly expressed proteins. Electrophoresis Apr 2009, 30(8):1306-1328.
32. Lamanda A., Zahn A., Roder D., Langen H. Improved Ruthenium II tris (bathophenantroline disulfonate) staining and destaining protocol for a better signal-to-background ratio and improved baseline resolution. Proteomics Mar 2004, 4(3):599-608.
33. Zellner M., Babeluk R., Diestinger M., Pirchegger P., Skeledzic S., Oehler R. Fluorescence-based Western blotting for quantitation of protein biomarkers in clinical samples. Electrophoresis Sep 2008, 29(17):3621-3627.
34. Crook R., Hardy J., Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods Aug 1994, 53(2):125-127.
35. Vandesompele J., De P.K., Pattyn F., Poppe B., Van R.N., De P.A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol Jun 18 2002, 3(7). [RESEARCH0034].
36. Harro M., Eensoo D., Kiive E., Merenakk L., Alep J., Oreland L., et al. Platelet monoamine oxidase in healthy 9- and 15-years old children: the effect of gender, smoking and puberty. Prog Neuropsychopharmacol Biol Psychiatry Nov 2001, 25(8):1497-1511.
37. Benjamini Y., Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annal Stat 2001, 29(4):1165-1188. [Ref Type: Abstract].
38. Zellner M., Babeluk R., Jakobsen L.H., Gerner C., Umlauf E., Volf I., et al. A proteomics study reveals a predominant change in MaoB expression in platelets of healthy volunteers after high protein meat diet: relationship to the methylation cycle. J Neural Transm May 2011, 118(5):653-662.
39. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA Apr 23 2003, 289(16):2094-2103.
40. Matsushima H., Shimohama S., Fujimoto S., Takenawa T., Kimura J. Changes in platelet phospholipase C protein level and activity in Alzheimer's disease. Neurobiol Aging Nov 1995, 16(6):895-900.
41. Blazquez L., Otaegui D., Saenz A., Paisan-Ruiz C., Emparanza J.I., Ruiz-Martinez J., et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci Lett Oct 9 2006, 406(3):235-239.
42. Davidson Y., Gibbons L., Pritchard A., Hardicre J., Wren J., Stopford C., et al. Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord 2007, 23(1):60-66.
43. Kuwano R., Miyashita A., Arai H., Asada T., Imagawa M., Shoji M., et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. Hum Mol Genet Jul 1 2006, 15(13):2170-2182.
44. Jossan S.S., Gillberg P.G., d'Argy R., Aquilonius S.M., Langstrom B., Halldin C., et al. Quantitative localization of human brain monoamine oxidase B by large section autoradiography using l-[3H]deprenyl. Brain Res Apr 26 1991, 547(1):69-76.
45. Gottfries C.G. Neurochemical aspects on aging and diseases with cognitive impairment. J Neurosci Res Dec 1990, 27(4):541-547.
46. Gulyas B., Pavlova E., Kasa P., Gulya K., Bakota L., Varszegi S., et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography. Neurochem Int Jan 2011, 58(1):60-68.
47. Nakamura S., Kawamata T., Akiguchi I., Kameyama M., Nakamura N., Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 1990, 80(4):419-425.
48. Fowler J.S., Volkow N.D., Logan J., Wang G.J., MacGregor R.R., Schyler D., et al. Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal. Synapse Oct 1994, 18(2):86-93.
49. May T., Greube A., Strauss S., Heineke D., Lehmann J., Rommelspacher H. Comparison of the in vitro binding characteristics of the beta-carbolines harman and norharman in rat brain and liver and in bovine adrenal medulla. Naunyn Schmiedebergs Arch Pharmacol Mar 1994, 349(3):308-317.
50. Launay J.M., Del P.M., Chironi G., Callebert J., Peoc'h K., Megnien J.L., et al. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS One 2009, 4(11):e7959.
51. Oreland L., Damberg M., Hallman J., Garpenstrand H. Smoking only explains part of the associations between platelet monoamine oxidase activity and personality. J Neural Transm May 2002, 109(5-6):963-975.
52. Bongioanni P., Gemignani F., Boccardi B., Borgna M., Rossi B. Platelet monoamine oxidase molecular activity in demented patients. Ital J Neurol Sci Jun 1997, 18(3):151-156.
53. Emilsson L., Saetre P., Balciuniene J., Castensson A., Cairns N., Jazin E.E. Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett Jun 21 2002, 326(1):56-60.
54. Fuso A., Scarpa S. One-carbon metabolism and Alzheimer's disease: is it all a methylation matter?. Neurobiol Aging Jul 2011, 32(7):1192-1195.
55. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol Jan 2006, 147(Suppl 1):S287-S296.
56. Steventon G., Humfrey C., Sturman S., Waring R.H., Williams A.C. Monoamine oxidase B and Parkinson's disease. Lancet Jan 20 1990, 335(8682):180.
57. Zeller E.A., Boshes B., Arbit J., Bieber M., Blonsky E.R., Dolkart M., et al. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and l-dopa on platelet monoamine oxidase. J Neural Transm 1976, 39(1-2):63-77.
58. Kuhn W., Muller T., Gerstner A., Winkel R., Goetz M.E. Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls. Can J Neurol Sci Aug 1998, 25(3):249-251.
59. Kuiper M.A., Konings C.H., Bergmans P.L., Wolters E.C. Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients. J Neurol Sci Jul 1993, 117(1-2):41-45.
60. Husain M., Shukla R., Dikshit M., Maheshwari P.K., Nag D., Srimal R.C., et al. Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease. Neurochem Res Aug 2009, 34(8):1427-1432.
61. Zhou G., Miura Y., Shoji H., Yamada S., Matsuishi T. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiatry Feb 2001, 70(2):229-231.
62. Finch C.C., Ho S.L., Williams A.C., Billett E.E. Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls. Prog Brain Res 1995, 106:85-90.
63. Andreu N., mase-Michel C., Senard J.M., Rascol O., Montastruc J.L. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity. Mov Disord May 1997, 12(3):293-296.
64. Ahlskog J.E., Uitti R.J., Tyce G.M., O'Brien J.F., Petersen R.C., Kokmen E. Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. J Neurol Sci Mar 1996, 136(1-2):162-168.
65. Meszaros Z., Borcsiczky D., Mate M., Tarcali J., Szombathy T., Tekes K., et al. Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease. Neurochem Res Jun 1998, 23(6):863-868.
66. Bauco C., Golosio F., Cinti A.M., Borriello C., Raganato P., Cicconetti P., et al. Functional status and well-being of centenarians. Arch Gerontol Geriatr 1996, 22(Suppl 1):363-366.
67. Kennedy B.P., Ziegler M.G., Alford M., Hansen L.A., Thal L.J., Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J Neural Transm Jul 2003, 110(7):789-801.
68. Gotz M.E., Fischer P., Gsell W., Riederer P., Streifler M., Simanyi M., et al. Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement Geriatr Cogn Disord Mar 1998, 9(2):74-77.
69. Tong Y., Zhou W., Fung V., Christensen M.A., Qing H., Sun X., et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm Mar 2005, 112(3):455-469.
70. Borghi R., Patriarca S., Traverso N., Piccini A., Storace D., Garuti A., et al. The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging Jul 2007, 28(7):1009-1014.
71. Girgin S.F., Sozmen E.Y., Ersoz B., Mentes G. Link between monoamine oxidase and nitric oxide. Neurotoxicology Jan 2004, 25(1-2):91-99.
72. de Lima M.N., Laranja D.C., Caldana F., Bromberg E., Roesler R., Schroder N. Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol Jun 2005, 40(6):506-511.
73. Filip V., Kolibas E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci May 1999, 24(3):234-243.